CARE Ratings Plans New York Investor Meeting on March 26

CARE Ratings is set to host an Analyst/Institutional Investor Meet in New York on March 26, 2026. Organized by Nuvama Institutional Equities and TenCore Partners, the session will focus on publicly available information. Investors will look for clarity on the company's outlook, with past regulatory actions remaining a key point of attention.

Meeting Details

The meeting is scheduled for March 26, 2026, in New York. Nuvama Institutional Equities and TenCore Partners are organizing the event, which will cover information already available in the public domain.

Why This Meet Matters

These meetings are key for building investor confidence and transparency. They provide stakeholders insight into CARE Ratings' strategy and market position. The sessions offer a platform for the company to highlight its value in a competitive market.

Company Background

CARE Ratings, established in 1993, is a prominent Indian credit rating agency serving diverse sectors. The company recently reported strong Q3 FY26 results, with revenue up 16% YoY and profit after tax (PAT) up 29%. In a strategic move, CARE Ratings also approved a joint venture, 'Operus Limited', with Vestian Global Work Place Services.

Potential Outcomes

This engagement could boost visibility among international investors, offering a platform to present the company's growth strategy and future plans. It may also lead to a clearer market perception of CARE Ratings' financial health and operational progress, while allowing investors to ask questions about public disclosures.

Risks to Watch

The meeting schedule could change due to unforeseen circumstances. Past regulatory issues, such as SEBI's actions concerning a former CEO for interference in ratings and warnings for operational problems, could affect investor views on governance.

Competitor Snapshot

CARE Ratings operates in a sector with key competitors like ICRA Ltd. and CRISIL Ltd. As of March 23, 2026, CARE Ratings had a market cap of ₹4,503 Cr, comparable to ICRA (₹5,265.5 Cr) and CRISIL (₹4,164.1 Cr).

Recent Financial Performance

CARE Ratings reported ₹11,212.42 lakh in revenue for Q3 FY26, a 16% YoY increase. Profit After Tax (PAT) for Q3 FY26 stood at ₹3,653.96 lakh, a 29% YoY rise.

Looking Ahead

Investors will track any key takeaways or forward-looking statements from the New York meeting. The company's efforts to enhance investor relations and address past governance concerns will also be watched. Performance updates following the Operus Limited joint venture and future financial results will be important.